The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan or a pharmaceutically acceptable salt thereof and optionally another therapeutic agent (b) methods of using such pharmaceutical dosage forms to treat nephropathy chronic kidney disease and/or other conditions (c) kits comprising such pharmaceutical dosage forms and optionally a second pharmaceutical dosage form comprising another therapeutic agent (d) methods for the preparation of such pharmaceutical dosage forms and (e) pharmaceutical dosage forms prepared by such methods.